Ganciclovir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
** Can also develop through mutations in the target UL54 DNA polymerase |
** Can also develop through mutations in the target UL54 DNA polymerase |
||
* Oral bioavailability 6-8% |
* Oral bioavailability 6-8% |
||
| + | * Indications: {{#ask: [[Is treated by::ganciclovir]] | default=none}} |
||
[[Category:Antivirals]] |
[[Category:Antivirals]] |
||
Revision as of 21:58, 23 October 2019
- Guanosine nucleoside analogue similar to acyclovir
- Inhibits all human herpesviruses by inhibiting DNA polymerase
- Resistance in CMV
- Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
- Can also develop through mutations in the target UL54 DNA polymerase
- Oral bioavailability 6-8%
- Indications: CMV after hematopoietic stem cell transplantation, CMV after solid organ transplantation, Congenital CMV, Cytomegalovirus, Herpesviridae, Macacine alphaherpesvirus 1, Post-transplant acute limbic encephalitis
